Streamlining Tezspire Prior Authorization for Orthopedics

Understanding Tezspire Prior Authorization in an Orthopedic Context

Tezspire (tezepelumab) is a targeted biologic therapy for severe asthma, not a primary medication prescribed by orthopedic specialists. However, orthopedic practices often treat patients with complex medical histories, including those requiring advanced therapies for co-morbid conditions like severe asthma. In such scenarios, particularly within multi-specialty groups or health systems, orthopedic PA teams may need to coordinate or manage prior authorizations for medications like Tezspire to ensure comprehensive patient care, especially in pre-operative optimization.

Documentation Requirements for Tezspire PA

Prior authorization for Tezspire typically requires comprehensive documentation confirming a diagnosis of severe asthma, evidence of inadequate control despite conventional therapies (e.g., high-dose inhaled corticosteroids), and specific biomarker levels (e.g., elevated blood eosinophil count or fractional exhaled nitric oxide [FeNO]). For an orthopedic practice, compiling this evidence often necessitates collaboration with pulmonology or primary care, integrating data from various EMR sources to meet payer-specific criteria.

Navigating Co-morbid Drug PAs in Orthopedic Workflows

• Clinical Specialization Gap: Orthopedic teams may lack direct familiarity with the specific clinical criteria and documentation nuances for non-orthopedic biologics.
• Data Siloing: Relevant clinical data (pulmonary function tests, prior medication trials) might reside in different departmental EMR modules, hindering efficient compilation.
• Payer Policy Diversity: Payer policies for biologics like Tezspire vary significantly in step-therapy requirements, diagnostic criteria, and approved prescribers.
• Time Sensitivity: Coordinating complex drug PAs alongside time-sensitive orthopedic surgical clearances adds significant operational pressure.
• Peer-to-Peer Review: Potential for peer-to-peer reviews with a pulmonologist or allergist, requiring specific clinical expertise not typically resident in an orthopedic PA team.

Common Denial Reasons for Biologics Like Tezspire

Denials for biologics such as Tezspire often stem from insufficient documentation of failed prior therapies (step therapy), lack of clear medical necessity based on diagnostic criteria, or absence of required biomarker results. In an orthopedic context, these denials can delay critical pre-operative optimization or ongoing management of co-morbid conditions, underscoring the need for robust PA processes that can proactively address these common pitfalls.

Klivira's Role in Streamlining Diverse PA Requests

Klivira's prior authorization automation platform is designed to manage the full spectrum of PA requests, including those for specialty medications like Tezspire, even when encountered within an orthopedic workflow. By integrating with EMRs and payer portals, Klivira centralizes documentation, tracks payer-specific clinical criteria, and orchestrates multi-specialty data retrieval, enabling orthopedic PA teams to efficiently process complex requests for co-morbid conditions without diverting focus from core orthopedic PAs for imaging, procedures, and DME.

Enhancing Orthopedic Efficiency for All PA Types

Beyond managing specific drug PAs, Klivira addresses the high PA volume per surgeon practice and the pre-operative scheduling pressures common in orthopedics. Our platform supports the multi-step PA cascade for imaging-then-surgery sequences and streamlines interactions with specialty benefit-management vendors for advanced imaging, ensuring that all PA types—from complex biologics to routine surgical clearances—are handled with maximal efficiency.